Shots:

• The US FDA has granted FTD for GLR2007 for the treatment of patients with glioblastoma and application is eligible for Rolling Review and for Accelerated Approval and Priority Review
• The Designation evaluate to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need
• GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor for the treatment of advanced solid tumors including glioblastoma- an aggressive form of brain cancer with a low survival rate

 ­ Ref: PRNewswire | Image: Gan & Lee